What the FDA labels say about taking them together
Atorvastatin and glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.).
What does the atorvastatin label say about glecaprevir/pibrentasvir?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the glecaprevir/pibrentasvir label say about atorvastatin?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Atorvastatin Lovastatin Simvastatin; Effect on Concentration: ↑ atorvastatin ↑ lovastatin ↑ simvastatin; Clinical Comments: Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with these statins is not recommended.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Glecaprevir/pibrentasvir | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $152.98 per tablet 100-40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once